Designing non-clinical safety evaluation programmes: The view of the clinician
1. Experience with biotechnologically derived pharmaceuticals to treat auto-immune diseases provides an example of the pharmacological and safety information pertinent to first entry into man, and the relevance of animal data in support of early clinical trials.
KeywordsProtein Agent Soluble Cytokine Receptor Preclinical Toxicology Model Hypothesis Testing Multiple Animal Species
Unable to display preview. Download preview PDF.
- Bugelski P, Griswold D et al. (1996). Pharmacology and safety of anti-CD4 antibody IDEC-CE9.1 in HuCD4 transgenic mice. Arthritis & Rheumatism, 39(9): 5247.Google Scholar